Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis

• Published in: BMJ Vol. 318; no. 7190; pp. 1031 - 1035
• Main Authors: Evans, E Glyn V, Sigurgeirsson, Bárdur
• Format: Journal Article
• Language: English
• Published: London British Medical Journal Publishing Group 17.04.1999; British Medical Association; BMJ Publishing Group LTD; BMJ Publishing Group; British Medical Journal
• Edition: International edition
• Subjects: Antibiotics. Antiinfectious agents. Antiparasitic agents; Antifungal agents; Biological and medical sciences; Capsules; Dermatophytes; Drug therapy; Feet; Infections; Medical cures; Medical research; Medical sciences; Medical treatment; Mycology; Onychomycosis; Pharmacology. Drug treatments; Placebos; Toenails; Writing tablets; United Kingdom; Europe; Human; Skin disease; Mycosis; Continuous; Treatment efficiency; Toe; Allylic compound; Terbinafine; Infection; Antifungal agent; Chemotherapy; Nail(anatomy); Amine; Treatment; Intermittent; Double blind study; Triazole derivatives; Nail disease; Adult; Elderly; Itraconazole
• ISSN: 0959-8138; 0959-8146; 1468-5833; 1756-1833
• DOI: 10.1136/bmj.318.7190.1031

Abstract Objective: To compare the efficacy and safety of continuous terbinafine with intermittent itraconazole in the treatment of toenail onychomycosis. Design: Prospective, randomised, double blind, double dummy, multicentre, parallel group study lasting 72 weeks. Setting:35 centres in six European countries. Subjects: 496 patients aged 18 to 75 years with a clinical and mycological diagnosis of dermatophyte onychomycosis of the toenail. Interventions: Study patients were randomly divided into four parallel groups to receive either terbinafine 250 mg a day for 12 or 16 weeks (groups T12 and T16or itraconazole 400 mg a day for 1 week in every 4 weeks for 12 or 16 weeks (groups I and I). Main outcome measures: Assessment of primary efficacy at week 72 was mycological cure, defined as negative results on microscopy and culture of samples from the target toenail. Results: At week 72 the mycological cure rates were 75.7% (81/107) in the T12 group and 80.8% (80/99) in theT16 group compared with 38.3% (41/107) in theI group and 49.1 % (53/108) in the I4 group.All comparisons (T v I,T12 vI4, T16v I3, T16 vI4) showed significantly higher cure rates in the terbinafine groups (all P<0.0001). Also, all secondary clinical outcome measures were significantly in favour of terbinafine at week72. There were no differences in the number or type of adverse events recorded in the terbinafine or itraconazole groups. Conclusion: Continuous terbinafine is significantly more effective than intermittent itraconazole in the treatment of patients with toenail onychomycosis.